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As the patient had recently taken dabigatran, he was administered 5 g of idarucizumab in 2 dos es (both 2.5 g in 50 ml, administered as a quick 5 minute intravenous bolus, with a 5 minute in terval between the doses). Idarucizumab is a frag ment of a monoclonal antibody that restores sys temic blood coagulation and enables fibrin to be formed again in patients treated with dabigatran etexilate. 1 Following the administration of ida rucizumab, the APTT was 37 s and prothrombin time-18 s. After 2 hours, the patient was trans ferred to a cardiac surgery department to under go coronary artery bypass surgery and mitral valve annuloplasty. Unfractionated heparin was used during the 6 hour procedure, and protamine sulfate-at the end of surgery. Hemostasis was impaired, which could result from the fact that dual antiplatelet therapy had been implemented. The patient survived the surgery, and extracorpo real circulation lasted 4.5 hours. He was taken off the ventilator after 4 days, and intraaortic bal loon pump was removed after 5 days. The patient was discharged after 16 days of treatment. As an ticoagulation therapy, low molecular weight hep arin was used for a few days, followed by warfa rin. During hospitalization, no procoagulant ef fects were observed.
Acute cardiac conditions requiring surgical treatment very rarely necessitate the use of ida rucizumab. In REVERSE AD™, a phase III trial evaluating the efficiency and safety of dabigatran reversal with idarucizumab before urgent surgi cal treatment, only 2 of the 39 patients had car diac disease (dissecting aortic aneurysm in one patient and cardiac tamponade in the other). Among the 90 study participants, thrombotic An 86 year old man with paroxysmal atrial fibril lation was admitted to a cardiac intensive care unit (ICU) due to loss of consciousness following angina pectoris. An electrocardiogram (ECG) in the ambulance demonstrated a complete atrio ventricular block. While in the ICU, episodes of severe angina continued, and the patient was he modynamically unstable with features of pulmo nary congestion. His heart rate was 100 bpm and blood pressure-95/65 mm Hg. As anticoagula tion therapy, he received dabigatran (110 mg orally twice daily), and the last dose was administered 2 hours before admission. Laboratory tests revealed macrocytic anemia, an international normalized ratio of 1.36, prothrombin time of 15.5 s (refer ence range, 9.4-12.5 s), activated partial throm boplastin time (APTT) of 34 s (<37 s), brain natri uretic peptide levels of 640 pg/ml (0 -100 pg/ml), troponin I levels of 18.5 ng/ml (<0.04 ng/ml), cre atinine levels of 1.2 mg/dl, and estimated glomer ular filtration rate of 60.4 ml/min/1.73 m 2 . Abnor malities on ECG suggested significant myocardial ischemia (FIGURE 1A-1C) . The complete atrioventric ular block registered in the ambulance subsided on admission, and the patient developed a sinus rhythm of 100 bpm with right bundle branch block. However, only half an hour after admis sion, the ECG showed the sinus rhythm of 100 bpm with left bundle branch block. Transthorac ic echocardiography revealed decreased contrac tility with a left ventricular ejection fraction of 35%. Severe mitral regurgitation and the vena contracta at 0.8 cm (FIGURE 1D) were also noted. The patient was administered 600 mg of clopido grel and 300 mg of aspirin. Subsequently, he un derwent coronary angiography, which revealed 3 vessel disease with left coronary artery steno sis (FIGURE 1E-1J) . He was consulted by a cardiac
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Idarucizumab: a quick and effective antidote administered prior to coronary artery bypass surgery and mitral valve annuloplasty in a patient treated with dabigatran of a patient with 3 vessel disease, left coronary artery stenosis, and severe mitral regurgitation who was referred for an urgent cardiac surgery as a life saving procedure and who received idaru cizumab as an effective antidote for dabigatran.
events were reported only in 5; however, none of them received anticoagulation therapy at that time. In the present case, no thrombotic compli cations were observed after the surgery; howev er, the results of REVERSE AD™ indicate a risk of thrombotic events in patients not receiving anticoagulation therapy and suggest reintroduc tion of the therapy as soon as possible.
2,3 The use of idarucizumab has been reported in patients treated with dabigatran and requiring an ur gent surgery due to an acute dissecting aortic aneurysm or life threatening bleeding.
4,5 How ever, to our knowledge, this is the first report 
